Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 5
Primary Industries
- Drugs
- Alzheimer’s disease
- Brain Waves
- Disease
- Parkinsons Disease
- Drug Discovery
- Therapeutic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 209551
License Grant
The French Licensor grants a worldwide exclusive right and license in the Field under the Licensor Data, Inventions and interest in Joint Patent Rights and Joint Inventions to the extent necessary or useful to carry out Licensees research responsibilities under the Research Plan in accordance with this Agreement, and an exclusive right and license under the Licensor Data, Inventions and interest in Joint Patent Rights and Joint Inventions to develop, manufacture, have manufactured, use, commercialize, distribute for sale and sell Pharmaceutical Specialties containing Ampakines.
License Property
The licensed property is pertaining to a class of proprietary pharmaceuticals called Ampakines(R). Certain of these Ampakines have the potential to modulate and treat cognitive impairment and dementia.
Ampakines are a class of drugs that bind to the glutamatergic AMPA receptor, enhancing its activity by slowing deactivation and attenuating desensitization of AMPA receptor currents, increasing synaptic responses and enhancing LTP.
Field of Use
The Field is the use of Ampakines for the treatment of declines in cognitive or performance associated with aging, and neurodegenerative diseases, including such as but not limited to Alzheimers disease, Parkinsons disease, multiple sclerosis, and Amyotrophic Lateral Sclerosis.
IPSCIO Record ID: 273373
License Grant
This Patent assignment and Option and Amended and Restated agreement is to restructure the relationship to terminate and supersede the Prior Agreement with this Amended and Restated Agreement so that the French Licensee will own all rights to the composition of matter patents for CX1632, Licensee will have a worldwide sublicense with respect to products containing CX1632 to the method of use patents licensed by Licensor from The Regents of the University of California, and Licensor will have a worldwide license to Licensor Know-How with respect to products containing CX1632.
For the License of Licensor Know-How, Licensor grants to the French Licensee a perpetual, exclusive, even as to Licensor license, with the right to sublicense, to use the Licensor Know How inside the Field, including to develop, have developed, manufacture, have manufactured, use, commercialize, have commercialized, distribute and have distributed for sale and sell Pharmaceutical Specialties in the Territory limited specifically to use with CX1632 or combination products which include CX1632.
Licensor grants an option between the Effective Date and October 31, 2011, exercisable upon written notice from Licensee, to an exclusive, even as to Licensor sublicense, with the right to further sublicense, to use the University License Rights inside the Field, including to further develop, have developed, manufacture, have manufactured, use, commercialize, have commercialized, distribute or have distributed for sale and sell Pharmaceutical Specialties in the Territory.
Licensor grants an exclusive option during the Option Period, exercisable upon written notice from Licensee, to acquire all right, title and interest in and to the Assigned Licensor Patent Rights.
License Property
The compound is Cordi, A and G Rogers, 3-substituted (1,2,3)-Benzotriazinone Compound for enhancing Glutamatergic Synaptic Responses.
Field of Use
The Field shall mean the use of CX1632 in humans.
CX1632 comprises a pharmaceutical medicine used for treating memory and cognitive impairments in patients with Alzheimer's disease and other disorders.
IPSCIO Record ID: 299293
License Grant
The University grants a license under Universitys Patent Rights to make, have made, use, and sell Licensed Products and to practice Licensed Method in the Territory.
License Property
The invention, patents and methosd are for Drugs that Enhance Synaptic Responses Mediated by AMPA Receptors. The AMPA-type glutamate receptoris a complex of proteins that is involved in communication between nerve cells in the human brain.
Field of Use
AMPAKINE® technology is for the treatment of schizophrenia and depression.
Licensee is engaged in the discovery and development of innovative pharmaceuticals for the treatment of neurodegenerative diseases and other neurological and psychiatric disorders.
IPSCIO Record ID: 300615
License Grant
This amendment clarifies terms, including third party royalties. In the original license, the University granted a license under Universitys Patent Rights to make, have made, use, and sell Licensed Products and to practice Licensed Method in the Territory. The University also granted the right to issue sublicenses to third parties to make, have made, use, perform research on, and sell Licensed Products and to practice Licensed Method, provided Cortex has current exclusive rights thereto under this Agreement.
License Property
The invention, patents and methosd are for Drugs that Enhance Synaptic Responses Mediated by AMPA Receptors. The AMPA-type glutamate receptoris a complex of proteins that is involved in communication between nerve cells in the human brain.
Field of Use
Licensee is engaged in the discovery and development of innovative pharmaceuticals for the treatment of neurodegenerative diseases and other neurological and psychiatric disorders.
IPSCIO Record ID: 294263
License Grant
Commercial Licenses to Licensee Subject to the terms and conditions of this Agreement, Licensor hereby grants to Licensee (i) an exclusive worldwide, royalty-bearing license during the Agreement Term, including the right to sublicense, under the Licensor IP and Joint IP to make, use, import, sell and offer to sell Products and (ii) a non-exclusive, worldwide perpetual, royalty-free license, with the right to sublicense, under the Licensor IP to make, use, import, sell, and offer to sell biomarkers and diagnostics relating to Products. The license granted shall survive the expiration or termination of the Agreement Term.
License Property
The goal of the Collaboration is to discover compounds directed against the pathology mediated by or directly associated with the protein tau in Alzheimers disease (Compounds) and to develop such Compounds as pharmaceutical products (Products).
Combination Product means any pharmaceutical product which contains one or more pharmacologically or therapeutically active compound(s), product(s) and/or ingredient(s) in addition to Product.
Licensor will remain the sole owner of or otherwise shall continue to control rights in all IP relating to any and all Materials, information, plans or methods, except for Products, that may be disclosed to Licensee or developed solely by Licensor, or licensed to Licensor prior to or separate from performance of the Collaboration (Licensor Existing IP).
All IP conceived in the execution of the Collaboration solely by Licensor, except for Product-related IP, will be owned by Licensor (Licensor New IP)
All IP in the Field conceived in the execution of the Collaboration jointly by Licensor and Licensee, except for Product-related IP, will be owned jointly by Licensor and Licensee (Joint IP), provided that all IP in the Field created solely by any staff at Party A will be owned by Party A and licensed to Licensor under the Party A Agreements, and will be considered part of the Licensor IP licensed to Licensee under this Agreement.
Field of Use
The field in research and development of Compounds in the field of the following neurodegenerative diseases Alzheimers disease; frontotemporal dementia; Pick s disease; and progressive supranuclear palsy.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
